Navigation Links
Neuradiab in Medical News

Bradmer provides Phase III Neuradiab trial update and guidance

TSX: BMR TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug ...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...equally. We continue to evaluate opportunities to maximize the value of the neuradiab asset, however a substantial portion of the existing cash on hand will be u...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2009 first quarter operational and financial results

...luate strategic options. "Despite our pride in the progress made bringing neuradiab from a single-site Phase II program to a multicenter Phase III registration...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...tinuing to evaluate strategic options. "We have successfully transitioned neuradiab from a Phase II compound with compelling results at a single site to a cGMP...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer implements cash conservation plan

...tends to maintain the ability to pursue business development strategies for neuradiab and is continuing to explore opportunities that would permit further develo...lment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...l patient survival from 53 to 64 weeks. About neuradiab neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency. Bradmer Pharmaceuticals ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

...ponse of newly diagnosed GBM patients treated with neuradiab as an adjunct to the current standard of care, con...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...

Bradmer announces 2008 third quarter operational and financial results

...ART Trial and successfully dosed patients with neuradiab at multiple sites; - Announced new data from the...llow a two week extension of the shelf life of neuradiab beyond the current six-day specification; and ...y to provide a definitive answer on the benefit of neuradiab in the newly diagnosed GBM population." The Phas...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Neuradiab in Medical Technology

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ical trial, termed the GLASS-ART Trial, evaluating neuradiab as an adjunct therapy to the current standard of c...e control arm. "These PFS data from the Phase II neuradiab trials exceed the results achieved in any other cl...nt of median overall survival, the opportunity for neuradiab to demonstrate a patient benefit via the parameter...
Neuradiab in Biological Technology

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy for patien...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Other Tags
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
(Date:7/13/2014)... 13, 2014 Hope Palliative & Hospice Care ... support group at the Tamarack Senior Living Community in Palatine, ... 10:30 A.M. on the 3rd Wednesdays of every month. ... the Tamarack Community located at 55 S. Greeley St. Palatine, ... and there is no cost for the group. , ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers ... added a new selection of beautiful evening dresses ... a promotion for these evening gowns. Now, everybody can ... providing thousands of graceful gowns in its online store. ... France, Italy and many other countries. They are highly ...
(Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
(Date:7/11/2014)... Research awarded Michael F. Holick, PhD, MD, of Boston ... V. Avioli Award. Holick, a professor of medicine, physiology ... the understanding of vitamin D and its role in ... of the American Society for Bone and Mineral Research ... research. It is named for ASBMR,s first president and ...
(Date:7/11/2014)... USC Stem Cell scientists have set a "mouse TRAP" ... described by a recent study published in the ... line uses a technique called TRAP to extract cellular ... , Invented by scientists at the Rockefeller Institute for ... tag to the protein-making machinery, or ribosomes, of the ...
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A new genome editing method brings the possibility of gene therapies closer to reality 2
Other Contents